Tobacco dependence treatment in patients with heart and lung disease: implications for intervention and review of pharmacological therapy.
Hays
J T
JT
Mayo Clinic, Mayo Nicotine Dependence Center, Rochester, MN 55905, USA. hays.taylor@mayo.edu
D000293:Adolescent; D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use; D001521:Behavior Therapy; D016642:Bupropion / Q000627:therapeutic use; D002638:Chewing Gum; D003327:Coronary Disease / Q000150:complications* / Q000401:mortality; D003376:Counseling; D018765:Dopamine Uptake Inhibitors / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008173:Lung Diseases, Obstructive / Q000150:complications* / Q000401:mortality; D008297:Male; D015201:Meta-Analysis as Topic; D009042:Motivation; D009538:Nicotine / Q000008:administration & dosage; D018722:Nicotinic Agonists / Q000008:administration & dosage; D016017:Odds Ratio; D017410:Practice Guidelines as Topic; D012307:Risk Factors; D012907:Smoking / Q000009:adverse effects*; D016540:Smoking Cessation; D000074606:Smoking Prevention; D013997:Time Factors; D014029:Tobacco Use Disorder / Q000188:drug therapy / Q000628:therapy*
D018687:Antidepressive Agents, Second-Generation; D002638:Chewing Gum; D018765:Dopamine Uptake Inhibitors; D018722:Nicotinic Agonists; D016642:Bupropion; D009538:Nicotine